PENNSTATE HERSHEY Cancer Institute

**OPEN CLINICAL TRIALS AT PENN STATE HERSHEY CANCER INSTITUTE**
**June 17, 2013**
**Adult Trials (pages 1-6) and Pediatric Trials (pages 7-9)**

| PI Name | Protocol No. | Title | CRC |
|---|---|---|---|
| **ADULT TRIALS** | | | |
| **BONE MARROW CONSORTIUM** | | | |
| Loughran, Thomas | LOUGHRAN-2003-260 | Pathogenesis of LGL Leukemia | Kendall Baab 717-531-6308 Pager 2970 |
| Loughran, Thomas | LOUGHRAN-2003-276 | Large Granular Lymphocyte (LGL) Leukemia Registry | Kendall Baab 717-531-6308 Pager 2970 |
| **BRAIN** | | | |
| Wagner, Henry | PSHCI-09-102 | Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1p/19q Deleted Anaplastic Glioma: The CATNON Intergroup Trial (**RTOG 0834**) | Missy Crain 717-531-0003 ext 289630 pager 0436 |
| Wagner, Henry | PSHCI-10-026 | Phase II/III Study of Image-Guided Radiosurgery/SBRT for Localized Spine Metastasis Coordinated by the Radiation Therapy Oncology Group (**RTOG 0631**) | Missy Crain 717-531-0003 ext 289630 pager 0436 |
| Glantz, Michael | PSHCI-11-119 | A Randomized, Double-blind, Controlled Phase IIb Study of the Safety and Efficacy of ICT-107 in Newly Diagnosed Patients with Glioblastoma Multiforme Following Resection and Chemoradiation (**ImmunoCellular**) | Carla Baynham 717-531-0003 ext 287366 |
| Glantz, Michael | PSHCI-11-012 | A Randomized Phase I/II Study of ABT-888 in Combination with Temozolomide in Recurrent (Temozolomide Resistant) Glioblastoma (**RTOG 0929**) | Carla Baynham 717-531-0003 ext 287366 |
| Glantz, Michael | PSHCI-12-032 | PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation: A Randomized Phase II Study (**(BrUOG) Brown University**) | Carla Baynham 717-531-0003 ext 287366 |
| Sheehan, Jonas | PSHCI-12-033 | Open-label Phase 1/2 (Safety Lead-in) Study of Trans Sodium Crocetinate (TSC) with Concomitant Treatment of Fractionated Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Patients to Evaluate Safety and Efficacy (**Diffusion Pharmaceuticals** ) | Carla Baynham 717-531-0003 ext 287366 |
| **BREAST** | | | |
| Smith, J Stanley | PSHCI-08-102 | A Phase II Trial Exploring the Success of Cryoablation Therapy in the Treatment of Invasive Breast Carcinoma (**Z1072**) | Jo Ann Fahringer 717-531-0003 ext 285237 pager 1845 |
| Smith, J Stanley | PSHCI-09-061 | A Phase III Clinical trial comparing Trastuzumab given concurrently with Radiation Therapy and Radiation Therapy alone for Women with HER2-Positive Ductal Carcinoma in Situ Resected by Lumpectomy (**B-43**) | Jo Ann Fahringer 717-531-0003 ext 285237 pager 1845 |
| Harvey, Harold | PSHCI-10-028 | Randomized Phase II Trial of ABT-888 vs. ABT-888 in Combination with Carboplatin in Patients with Stage IV BRCA-associated Breast Cancer (**NCI 8264**) | Jo Ann Fahringer 717-531-0003 ext 285237 pager 1845 |
| Cream, Leah | PSHCI-10-082 | A Phase II Prospective Trial Correlating Progression Free Survival with CYP2D6 Activity in Patients with Metastatic Breast Cancer Treated with Single Agent Tamoxifen (**E3108**) | Jo Ann Fahringer 717-531-0003 ext 285237 pager 1845 |
| Smith, J Stanley | PSHCI-11-017 | Phase III Randomized Study of Early Local Therapy Comprising Surgery Versus Standard Palliative Therapy for the Intact Primary Tumor in Patients With Stage IV Breast Cancer (**E2108**) | Jo Ann Fahringer 717-531-0003 ext 285237 pager 1845 |
| Harvey, Harold | PSHCI-11-018 | A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer (**NSABP B-47**) | Jo Ann Fahringer 717-531-0003 ext 285237 pager 1845 |
| Smith, J Stanley | PSHCI-11-076 | A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less (**S1007**) | Jo Ann Fahringer 717-531-0003 ext 285237 pager 1845 |

PENNSTATE HERSHEY Cancer Institute

**OPEN CLINICAL TRIALS AT PENN STATE HERSHEY CANCER INSTITUTE**
**June 17, 2013**
**Adult Trials (pages 1-6) and Pediatric Trials (pages 7-9)**

| PI Name | Protocol No. | Title | CRC |
|---|---|---|---|
| **BREAST** | | | |
| Lipton, Allan | PSHCI-11-090 | A Randomized Phase 2 Study of the Efficacy and Tolerability of Veliparib in Combination with Temozolomide or Veliparib in Combination with Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Subjects with BRCA1 or BRCA2 Mutation and Metastatic Breast Cancer (**ABBOTT LABS**) | Cindy Campbell Baird 717-531-5777 |
| Truica, Cristina | PSHCI-12-043 | A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer (**B-49**) | Jo Ann Fahringer 717-531-0003 ext 285237 pager 1845 |
| **CARCINOID SYNDROME** | **(No Carcinoid Syndrome trials as of 06/17/2013)** | | |
| **CORRELATIVE SCIENCE/BANKING** | | | |
| Claxton, David | CLAXTON-2000-186 | Blood and Bone Marrow Sampling for Tissue Banking | CRC 717-531-7417 |
| Claxton, David | PSHCI-08-065 | Biologic Studies of Experimental Anti-Cancer Therapeutics in Human Leukemia Cells | Brian Barth/David Claxton 717-531-8399 |
| Drabick, Joseph | PSHCI-10-061 | General Protocol for the Acquisition of Whole Blood for the Detection and Characterization of Circulating Tumor Cells and/or Tumor Specific Immunity/Immune Cell Activation for any Malignancy at any Stage of Disease | Joseph Drabick 717-531-8677 |
| Loughran, Thomas | PSHCI-08-070 | Sphingolipid Metabolism in Acute Myelogenous Leukemia | Su-Fern Tan 717-531-0003 ext 284204 |
| Rybka, Witold | ECOG-E3A05 | Ancillary Laboratory Protocol for Collecting Diagnostic Material on Patients Considered for Studies of Plasma Cell Disorders | CRC 717-531-7417 |
| Rybka, Witold | RYBKA-2002-197EP | Protocol for a Research Sample Repository for Allogeneic Hematopoietic Stem Cell Transplantation | CRC 717-531-7417 |
| **CORRELATIVE SCIENCE/BANKING** | | | |
| Rybka, Witold | RYBKA-2002-198EP | Protocol for a Research Database for Hematopoietic Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries | CRC 717-531-7417 |
| Smith, J Stanley | SMITH-2003-138 | Collection of Participant Blood, Tissue, and Phenotypic Data for Inclusion in a Repository and Use in Outcome Studies | Molly Pells 717-531-5794 pager 3037 |
| Neves, Rogerio | PSHCI-09-052 | The Collection of Blood, Tissue and Phenotypic Data in Patients diagnosed with Skin Cancers and Subsequent Metastases for Inclusion in a repository and use in outcome studies | Rogerio Neves 717-531-8371 |
| El-Deiry, Wakif | PSHCI-10-066 | Prevalence of Stem Cell and Prognostic Markers in Circulating Tumor Cells of Patients With Metastatic Colorectal Cancer Undergoing Chemotherapy | David Dicker 717-531-0003 ext 289624 |
| El-Deiry, Wakif | PSHCI-11-007 | Sensitivity of Colon Cancer Tissue and Stroma to Trail and Trail-Based Therapies | Wafik El-Deiry 717-531-3609 |
| El-Deiry, Wakif | PSHCI-11-064 | Plk2-TSK Interactions and Tumor Progression in Colorectal Cancer | Wafik El-Deiry 717-531-3609 |
| Goldenberg, David | PSHCI-10-030 | Pigmentation of Papillary Thyroid Carcinoma Lymph Node Metastases | David Goldenberg 717-531-8945 |
| Kaifi, Jussuf | PSHCI-12-058 | Perioperative Detection and Characterization of Circulating Tumor Cells in Patients Undergoing Colorectal Cancer Liver and Lung Metastasectomy | Jussuf Kaifi 717-531-5965 |
| Belani, Chandra | PSHCI-12-064 | Oncogenic Mutations/Gene Rearrangements in Patients with Advanced Adenocarcinoma Lung | Xin Liu 717-531-3073 |
| Belani, Chandra | PSHCI-12-094 | Characterization of Oncogenic Mutations in Patients with Advanced Squamous Cell Lung Cancer | Xin Liu 717-531-3073 |
| Belani, Chandra | PSHCI-12-109 | Oncogenic Driver Mutations/Biomarkers in Screening Participants for Early Detection of Lung Cancer | Xin Liu 717-531-3073 |
| Belani, Chandra | PSHCI-12-017 | Development of Proteomic Biomarkers for Early Lung Cancer Detection and Development | Wanda Neidig 717-531-1002 pager 3159 |

PENNSTATE HERSHEY Cancer Institute

**OPEN CLINICAL TRIALS AT PENN STATE HERSHEY CANCER INSTITUTE**
**June 17, 2013**
**Adult Trials (pages 1-6) and Pediatric Trials (pages 7-9)**

| PI Name | Protocol No. | Title | CRC |
|---|---|---|---|
| **GI** | | | |
| Moyer, Matthew | PSHCI-10-109 | Chemotherapy for Ablation and Resolution of Mucinous Pancreatic Cysts | Matthew Moyer 717-531-3694 |
| El-Deiry, Wakif | PSHCI-12-084 | Neoadjuvant FOLFOX and/or 5FUCMT vs PreOp Chemoradiation For Locally Adv Rectal CA (**1048**) | Michele St Pierre 717-531-0003 ext 287412 pager 2324 |
| **GU** | | | |
| Juliano, Justin | PSHCI-10-077 | A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy with or without Short-Term Androgen Deprivation Therapy for Patients With Intermediate-Risk Prostate Cancer (**R0815**) | Missy Crain 717-531-0003 ext 289630 pager 0436 |
| Juliano, Justin | PSHCI-11-086 | A Phase III Trial of Short Term Androgen Deprivation with Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPPORT) in Prostate Cancer Patients with a Rising PSA After Radical Prostatectomy (**RTOG 0534**) | Missy Crain 717-531-0003 ext 289630 pager 0436 |
| Juliano, Justin | PSHCI-11-087 | Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial (**RTOG 0924**) | Missy Crain 717-531-0003 ext 289630 pager 0436 |
| **GYN** | | | |
| Fanning, James | 187 | Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second Line Therapy | Ann Gelder 717-531-8144 pager 1488 |
| Fanning, James | 212 | A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12 Monthly Cycles of Single Agent Paclitaxel or Zyotax Versus No treatment Until Documented Relapse in Women with Advanced Ovarian or Primary Peritoneal Cancer who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy | Ann Gelder 717-531-8144 pager 1488 |
| Fanning, James | PSHCI-09-064 | A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel Alone or in Combination with Bevacizumab Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer (**GOG 213**) | Ann Gelder 717-531-8144 pager 1488 |
| Fanning, James | PSHCI-09-073 | A Randomized phase III trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma (**GOG 258**) | Ann Gelder 717-531-8144 pager 1488 |
| Fanning, James | PSHCI-09-079 | A Randomized Phase III Trial of Paclitaxel Plus Carboplatin vs Ifosfamide plus Paclitaxel in Chemotherapy Naïve Patients with Newly Diagnosed Stage I-IV, Persistent, or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus (**GOG 261**) | Ann Gelder 717-531-8144 pager 1488 |
| Fanning, James | PSHCI-10-034 | A Randomized, Phase III Evaluation of Docetaxel and Gemcitabine plus G-CSF with Bevacizumab versus Docetaxel and Gemcitabine plus G-CSF with Placebo in the Treatment of Recurrent or Advanced Leiomyosarcoma of the Uterus (**GOG 250**) | Ann Gelder 717-531-8144 pager 1488 |
| Fanning, James | PSHCI-10-048 | Expression of Opioid Growth Factor Peptide and Opioid Growth Factor Receptor in Ovarian Tissue | Dr Fanning 717 531 8144 |
| **HEAD AND NECK** | **(None as of 06/17/2013)** | | |
| **HEMATOLOGY/OTHER** | **(None as of 06/17/2013)** | | |

**OPEN CLINICAL TRIALS AT PENN STATE HERSHEY CANCER INSTITUTE**
**June 17, 2013**
**Adult Trials (pages 1-6) and Pediatric Trials (pages 7-9)**

| PI Name | Protocol No. | Title | CRC |
|---|---|---|---|
| **LEUKEMIA** | | | |
| Claxton, David | PSHCI-08-031 | A Phase 1 Trial of the Immunostimulant JVRS-100 for the Treatment of Patients with Relapsed or Refractory Leukemia | Christine Capper 717-531-0003 ext 285453 pager 4791 |
| Neal, Thomas | PSHCI-09-071 | Trial of Calfactant for ALI in Pediatric Leukemia and HSCT Patients | Thomas Neal 717-531-5337 |
| Claxton, David | PSHCI-09-083 | A Phase II Randomized Trial of Carboplatin and Topotecan; Flavopiridol, Mitoxantrone and Cytosine Arabinoside; and Sirolimus, Mitoxantrone, Etoposide and Cytosine Arabinoside for the Treatment of Adults with Primary Refractory or Initial Relapse of Acute Myelogenous Leukemia (AML) (**E1906**) | Brian Couch 717-531-0003 ext 285861 pager 0406 |
| Claxton, David | PSHCI-10-081 | A Phase III Randoized Study of Oral Sapacitabine in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia (**Cyclacel Ltd**) | Christine Capper 717-531-0003 ext 285453 pager 4791 |
| Claxton, David | PSHCI-10-088 | A Phase II Randomized Trial Comparing Standard and Low Dose Rituximab: Initial Treatment of Progressive Chronic Lymphocytic Leukemia in Elderly Patients Using Alemtuzumab and Rituximab (**E1908**) | Brian Couch 717-531-0003 ext 285861 pager 0406 |
| Claxton, David | PSHCI-10-091 | Phase II Study of Combination of Hyper-CVAD and Dasatinib with or without allogeneic stem cell transplant in Patients with Philadelphia (Ph) Chromosome Positive and/or Bcr-Abl Positive Acute Lymphoblastic Leukemia (ALL) (A BMT Study) (**S0805**) | Karli Schellenberg CRC 717-531-7417 pager 0608 |
| Claxton, David | PSHCI-11-002 | Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age >/= 60 years) (**E2906**) | Karli Schellenberg CRC 717-531-7417 pager 0608 |
| Rybka, Witold | PSHCI-11-040 | A randomized, prospective, double blind, placebo-controlled, phase 3 study of US-ATG-F prophylaxis as a supplement to standard of care prophylaxis to prevent moderate to severe chronic GVHD in adult acute myeloid leukemia, acute lymphoid leukemia, and myelodysplastic syndrome patients after allogeneic stem cell transplantation from unrelated donors (IV-ATG-SCT-01) (**Fresenius Biotech North America Inc.**) | Brian Couch 717-531-0003 ext 285861 pager 0406 |
| Rybka, Witold | PSHCI-11-070 | Phase I Dose Finding/Phase II Placebo-Controlled Trial of Eltrombopag During Consolidation Therapy in Adults with Acute Myeloid Leukemia (AML) in Complete Remission (PrE0901) | Brian Couch 717-531-0003 ext 285861 pager 0406 |
| Ehmann, W Christopher | PSHCI-12-079 | Inotuzumab Ozogamicin or Defined Investigator's Choice for Relapsed or Refractory CD22-Positive ALL | Brian Couch 717-531-0003 ext 285861 pager 0406 |
| **LYMPHOMA** | | | |
| Ehmann, W Christopher | PSHCI-09-035 | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III study of RAD001 Adjuvant Therapy in Poor Risk Patients with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 versus Matching Placebo after Patients have Achieved Complete Response with First-Line Rituximabchemotherapy (**Novartis**) | CRC 717-531-7417 |
| Rybka, Witold | PSHCI-11-100 | A 3-Arm Randomized Phase II Trial of Bendamustine-Rituximab (BR) Followed by Rituximab vs Bortezomib-BR (BVR) Followed by Rituximab vs BR Followed by Lenalidomide/Rituximab in High Risk Follicular Lymphoma (**E2408**) | Christine Capper 717-531-0003 ext 285453 pager 4791 |

**OPEN CLINICAL TRIALS AT PENN STATE HERSHEY CANCER INSTITUTE**
**June 17, 2013**
**Adult Trials (pages 1-6) and Pediatric Trials (pages 7-9)**

| PI Name | Protocol No. | Title | CRC |
|---|---|---|---|
| **MDS** **(None as of 06/17/2013)** | | | |
| **MELANOMA** | | | |
| Drabick, Joseph | PSHCI-09-030 | A Phase II Trial of Dasatinib in KIT-Positive Patients with Unresectable Locally Advanced or Stage IV Mucosal, Acral and Vulvovaginal Melanomas (**E2607**) | Missy Crain 717-531-0003 ext 289630 pager 0436 |
| Neves, Rogerio | PSHCI-08-059 | Multicenter Selective Lymphadenectomy Trial II (MSLT-II): A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients with Molecular or Histopathological Evidence of Metastases in the Sentinel Node, coordinated by the John Wayne Cancer Institute | Missy Crain 717-531-0003 ext 289630 pager 0436 |
| Neves, Rogerio | PSHCI-08-080 | Histological Features of Sentinel Lymph Node Biopsy for Malignant Melanoma as a Predictive Indicator for Completion Lymphadenectomy | Rogerio Neves 717-531-8371 |
| Drabick, Joseph | PSHCI-09-067 | Phase II Trial of High Dose Interleukin-2 followed by intermittent low dose Temozolomide in patients with Metastatic Malignant Melanoma | Missy Crain 717-531-0003 ext 289630 pager 0436 |
| Drabick, Joseph | PSHCI-11-072 | A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon α-2b for Resected High-risk Melanoma | Missy Crain 717-531-0003 ext 289630 pager 0436 |
| **MYELOFIBROSIS** | | | |
| Claxton, David | PSHCI-11-034 | An Open Label Assessment of Safety and Efficacy of Ruxolitinib (INCB018424) in Subjects with Primary Myelofibrosis, Post Essential Thrombocythemia-Myelofibrosis and Post Polycythemia Vera-Myelofibrosis who Have Platelet Counts of 50 X109/L to 100 X109/L (**Incyte Corporation**) | Christine Capper 717-531-0003 ext 285453 pager 4791 |
| **MYELOMA** | | | |
| Talamo, Giampaolo | PSHCI-11-015 | A Trial of Single Autologous Transplant with or without Consolidation Therapy versus Tandem Autologous Transplant with Lenalidomide Maintenance for Patients with Multiple Myeloma (**0702**) | Brian Couch 717-531-0003 ext 285861 pager 0406 |
| **OTHER** | | | |
| Rybka, Witold | ECOG-E3A05 | Ancillary Laboratory Protocol for Collecting Diagnostic Material on Patients Considered for Studies of Plasma Cell Disorders | CRC 717-531-7417 |
| Rybka, Witold | ECOG-E3903 | Ancillary Laboratory Protocol for Collecting Diagnostic Material on Patients Considered for ECOG Treatment Trials for Leukemia or Related Hematologic Disorders | CRC 717-531-7417 |
| Rybka, Witold | PSHCI-09-055 | A Multicenter Study of Hematopoietic Stem Cell Donor Safety | Michelle Carraher 717-531-5647 |
| Rybka, Witold | PSHCI-09-056 | Ancillary HROoL Investigation | Michelle Carraher 717-531-5647 |
| Rybka, Witold | PSHCI-11-042 | A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and Other Indications | Michelle Carraher 717-531-5647 |
| Pu, Jeffrey | PSHCI-12-106 | Using Human Tissue and Cells for Clonal Bone Marrow Disease Translational Research | Jeffery Pu 717-531-8399 |

PENNSTATE HERSHEY Cancer Institute

**OPEN CLINICAL TRIALS AT PENN STATE HERSHEY CANCER INSTITUTE**
**June 17, 2013**
**Adult Trials (pages 1-6) and Pediatric Trials (pages 7-9)**

| PI Name | Protocol No. | Title | CRC |
|---|---|---|---|
| **PHASE I** | | | |
| Belani, Chandra | PSHCI-09-007 | A Phase I, Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of Intravenous Dimethane Sulfonate (DMS612, NSC 281612) in Advanced Malignancies (**NCI 8283**) | Michele St Pierre 717-531-0003 ext 287412 pager 2324 |
| Belani, Chandra | PSHCI-10-021 | Phase I Study of ABT-888 in Combination with Gemcitabine in Patients with Advanced Malignancies (**NCI 8324**) | Michele St Pierre 717-531-0003 ext 287412 pager 2324 |
| Belani, Chandra | PSHCI-11-023 | A Phase I Pharmacokinetic Study of Belinostat for Solid Tumors and Lymphomas in Patients with Varying Degrees of Hepatic Dysfunction (**NCI 8846**) | Michele St Pierre 717-531-0003 ext 287412 pager 2324 |
| Belani, Chandra | PSHCI-11-093 | An Early Phase I Study of ABT-888 in Combination with Carboplatin and Paclitaxel in Patients with Hepatic or Renal Dysfunction and Solid Tumors (**NCI 8808**) | Michele St Pierre 717-531-0003 ext 287412 pager 2324 |
| Belani, Chandra | PSHCI-12-073 | A Phase I Study of Ipilimumab in Combination with Rituximab in Patients with Relapsed/Refractory CD20+ B-Cell Lymphoma (**9197**) | Karli Schellenberg CRC 717-531-7417 pager 0608 |
| Belani, Chandra | PSHCI-12-097 | Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination with Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer (**E2511**) | Rebecca Miller 717-531-1003 pager 3656 |
| Belani, Chandra | PSHCI-12-107 | A Phase 1 and Pharmacokinetic Single Agent Study of Romidepsin in Patients with, Lymphomas, Chronic Lymphocytic Leukemia and Select Solid Tumors and Varying Degrees of Liver Dysfunction (**NCI 9008**) | Michele St Pierre 717-531-0003 ext 287412 pager 2324 |
| **PREVENTION** **(None as of 06/17/2013)** | | | |
| **SARCOMA** | | | |
| Harvey, Harold | PSHCI-11-053 | A Randomized Controlled Study of YONDELIS® (Trabectedin) or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma Previously Treated with an Anthracycline and Ifosfamide | Missy Crain 717-531-0003 ext 289630 pager 0436 |
| **SKIN** **(None as of 06/17/2013)** | | | |
| **SYMPTOM MANAGEMENT/SUPPORTIVE CARE** **(None as of 06/17/2013)** | | | |
| **THORACIC** | | | |
| Almokadem, Salah | ECOG-E1505 | A Phase III Randomized Trial of Adjuvant Chemotherapy with or without Bevacizumab for Patients with completely Resected Stage IB (>/= 4 cm) - IIIA Non-Small Cell Lung Cancer (NSCLC) | Rebecca Miller 717-531-1003 pager 3656 |
| Belani, Chandra | PSHCI-08-082 | A Phase II study of Oral Sapacitabine in Patients with Previously Treated Non-Small Cell Lung Cancer (**Cyclacel**) | Rebecca Miller 717-531-1003 pager 3656 |
| Wagner, Henry | PSHCI-09-098 | Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Early Stage Centrally Located, Non-Small Cell Lung Cancer (NSCLC) in Medically Inoperable Patients (**RTOG 0813**) | Rebecca Miller 717-531-1003 pager 3656 |
| Wagner, Henry | PSHCI-10-092 | A Phase II Study of L-BLP25 and Bevacizumab in Unresectable Stage IIIA and IIIB Non-Squamous Non-Small Cell Lung Cancer after Definitive Chemoradiation (**E6508**) | Rebecca Miller 717-531-1003 pager 3656 |
| Belani, Chandra | PSHCI-10-096 | Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC (**E5508**) | Rebecca Miller 717-531-1003 pager 3656 |
| Belani, Chandra | PSHCI-12-101 | LUX-Lung EAP US; An open label expanded access program of afatinib (BIBW 2992) for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR mutation(s) (**Boehringer-Ingelheim**) | Rebecca Miller 717-531-1003 pager 3656 |
| Higgins, William | NCI-VN-Bronch | Piloting a Virtual Navigation (VN) System for Bronchoscopic Tissue Sampling | William Higgins 814-865-0186 ext 186 |

**OPEN CLINICAL TRIALS AT PENN STATE HERSHEY CANCER INSTITUTE**
**June 17, 2013**
**Adult Trials (pages 1-6) and Pediatric Trials (pages 7-9)**

| PI Name | Protocol No. | Title | CRC |
|---|---|---|---|
| **PEDIATRIC TRIALS** | | | |
| **BRAIN** | | | |
| McGregor, Lisa | COG-ACNS0331 | A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal Radiotherapy 18.00 Gy and Chemotherapy In Children with Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial | COG Contact 717-531-6012 |
| McGregor, Lisa | COG-ACNS0332 | Efficacy of Carboplatin Administered Concomitantly with Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other than Average Risk Medulloblastoma/PNET patients | COG Contact 717-531-6012 |
| McGregor, Lisa | COG-ACNS0822 | Randomized Phase II/III Study of Vorinostat and Local Irradiation or Temozolomide and Local Irradiation or Bevacizumab and Local Irradiation Followed by Maintenance Bevacizumab and Temozolomide in Children with Newly Diagnosed High-Grade Gliomas | COG Contact 717-531-6012 |
| McGregor, Lisa | COG-ACNS0831 | Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1-21 years | COG Contact 717-531-6012 |
| McGregor, Lisa | PSHCI-11-080 | Temozolomide with Irinotecan versus Temozolomide, Irinotecan plus Bevacizumab (NSC# 704865, BB-IND# 7921) for Recurrent/Refractory Medulloblastoma/CNS PNET of Childhood, A COG Randomized Phase II Screening Trial: A Groupwide Phase II Study COG **ACNS0821** | COG Contact 717-531-6012 |
| Comito, Melanie | PSHCI-12-004 | Phase II Trial Of Molecularly Determined Treatment Of Children And Young Adults With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas (**Dana Farber**) | Kathryn Byrnes 717-531-3098 |
| McGregor, Lisa | PSHCI-13-008 | A Phase 1/2 Study Of Suberoylanilide Hydroxamic Acid (SAHA, Vorinostat) And Local Irradiation, Followed By Maintenance SAHA In Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas (DIPG) (**ACNS0927**) | COG Contact 717-531-6012 |
| McGregor, Lisa | PSHCI-13-020 | Phase 2 Trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors (CNS GCT) (**ACNS1123**) | COG Contact 717-531-6012 |
| McGregor, Lisa | PSHCI-13-028 | A Phase II Randomized Trial of Lenalidomide (NSC # 703813, IND # 70116) in Pediatric Patients with Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas (**ACNS1022**) | COG Contact 717-531-6012 |
| **CORRELATIVE SCIENCE/BANKING** | | | |
| McGregor, Lisa | COG-ABTR01B1 | A Children's Oncology Group Protocol for Collecting and Banking Pediatric Research Specimens including Rare Pediatric Tumors. | COG Contact 717-531-6012 |
| McGregor, Lisa | COG-ACCRN07 | Protocol for the Enrollment on the Official COG Registry, the Childhood Cancer Research Network (CCRN) | COG Contact 717-531-6012 |
| McGregor, Lisa | COG-ACNS02B3 | A COG Protocol for Collecting and Banking Pediatric Brain Tumor Research Specimens | COG Contact 717-531-6012 |
| McGregor, Lisa | COG-AEWS07B1 | A Children's Oncology Group Protocol for Collecting and Banking Ewing Sarcoma Specimens | COG Contact 717-531-6012 |
| McGregor, Lisa | COG-AHOD04B1 | Hodgkin Disease Banking Study | COG Contact 717-531-6012 |
| McGregor, Lisa | COG-ANHL04B1 | Rare and Cutaneous Non-Hodgkin Lymphoma Registry | COG Contact 717-531-6012 |
| McGregor, Lisa | COG-AOST06B1 | A COG Protocol for Collecting and Banking Osteosarcoma Specimens | COG Contact 717-531-6012 |
| McGregor, Lisa | COG-AREN03B2 | Renal Tumor Classification, Biology, and Banking Study | COG Contact 717-531-6012 |
| McGregor, Lisa | COG-D9902 | A COG Soft Tissue Sarcoma Biology and Banking Protocol | COG Contact 717-531-6012 |

**OPEN CLINICAL TRIALS AT PENN STATE HERSHEY CANCER INSTITUTE**
**June 17, 2013**
**Adult Trials (pages 1-6) and Pediatric Trials (pages 7-9)**

| PI Name | Protocol No. | Title | CRC |
|---|---|---|---|
| **GI** | | | |
| McGregor, Lisa | COG-AHEP0731 | Treatment of Children with All Stages of Hepatoblastoma | COG Contact 717-531-6012 |
| Greiner, Robert | PSHCI-09-033 | Defibrotide for Patients with Hepatic Veno-Occlusive Disease (VOD): A Treatment IND Study (**Gentium**) | Kathryn Byrnes 717-531-3098 |
| **GU** | | | |
| McGregor, Lisa | COG-AREN0532 | Treatment for Very Low, Low and Standard Risk Favorable Histology Wilm's Tumor | COG Contact 717-531-6012 |
| McGregor, Lisa | COG-AREN0534 | Treatment for Patients with Bilateral, Multicentric, or Bilaterally-Predisposed Unilateral Wilms Tumor | COG Contact 717-531-6012 |
| **HEAD AND NECK** | | | |
| McGregor, Lisa | COG-ARET0321 | A Trial of Intensive Multi-Modality Therapy for Extra-Ocular Retinoblastoma | COG Contact 717-531-6012 |
| **LEUKEMIA** | | | |
| McGregor, Lisa | COG-AALL0434 | Intensified Methotrexate, Nelarabine and Augmented BFM therapy for Children & Young Adults with Newly Diagnosed T-cell ALL | COG Contact 717-531-6012 |
| McGregor, Lisa | COG-AALL05B1 | A Children's Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens | COG Contact 717-531-6012 |
| McGregor, Lisa | COG-AALL07P1 | Phase II Pilot Trial of Bortezomib (PS-341, Velcade, IND# 58443) in Combination with Intensive Re-induction therapy for children with relapsed ALL and Lymphoblastic Lymphoma | COG Contact 717-531-6012 |
| McGregor, Lisa | COG-AALL08B1 | Classification of Newly Diagnosed Acute Lymphoblastic Leukemia | COG Contact 717-531-6012 |
| McGregor, Lisa | COG-AALL0932 | Treatment of Patients with Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia | COG Contact 717-531-6012 |
| McGregor, Lisa | COG-AAML05P1 | Killer Immunoglobulin-like Receptor (KIR) Incompatible Hematopoietic Cell Transplantation (HCT) for Refractory and Relapsed Acute Myelogenous Leukemia (AML) and newly diagnosed AML with monosomy 7 or -5/5q- in Children | COG Contact 717-531-6012 |
| Greiner, Robert | PSHCI-11-115 | The Role of Minimal Residual Disease Testing before and after Hematopoietic Cell Transplantation for Pediatric Acute Myeloid Leukemia (**CIBMTR 09-MRD/IRB # 28709**) | Jenn Stokes 717-531-7765 |
| McGregor, Lisa | PSHCI-11-097 | A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006,IND#69896, NSC# 724772 for Patients with High Allelic Ratio FLT3/ITD (**AAML1031**) | COG Contact 717-531-6012 |
| McGregor, Lisa | PSHCI-11-107 | A Phase 2 Multi-Center, Historically-Controlled Study of Dasatinib Added to Standard Chemotherapy in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (**AALL1122** ) | Kathryn Byrnes 717-531-3098 |
| McGregor, Lisa | PSHCI-12-012 | A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC# 606869) in the Very High Risk Stratum (**AALL1131**) | COG Contact 717-531-6012 |

**OPEN CLINICAL TRIALS AT PENN STATE HERSHEY CANCER INSTITUTE**
**June 17, 2013**
**Adult Trials (pages 1-6) and Pediatric Trials (pages 7-9)**

| PI Name | Protocol No. | Title | CRC |
|---|---|---|---|
| **LYMPHOMA** | **(None as of 06/17/2013)** | | |
| **MDS** | | | |
| McGregor, Lisa | COG-AAML08B1 | Biology Study of Transient Myeloproliferative Disorder (TMD) in Children with Down Syndrome (DS) | COG Contact 717-531-6012 |
| **NEUROBLASTOMA** | | | |
| McGregor, Lisa | COG-ANBL0032 | A Phase III Randomized Study of Chimeric Antibody 14.18 (CH14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue | COG Contact 717-531-6012 |
| McGregor, Lisa | COG-ANBL00B1 | Neuroblastoma Biology Studies | COG Contact 717-531-6012 |
| **SARCOMA** | | | |
| McGregor, Lisa | COG-AEWS0331 | European Ewing Tumor Working Initiative of National Groups, Ewing Tumor Studies 1999 (Euro-E.W.I.N.G. 99) | COG Contact 717-531-6012 |
| McGregor, Lisa | PSHCI-11-036 | A Phase III Randomized Trial of Adding Vincristine-topotecan-cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-Metastatic Ewing Sarcoma (**AEWS1031**) | COG Contact 717-531-6012 |
| McGregor, Lisa | PSHCI-11-081 | A Pilot Study to Evaluate Novel Agents (Temozolomide and Cixutumumab [IMC-A12, Anti-IGF-IR Monoclonal Antibody, IND #100947, NSC #742460]) in Combination With Intensive Multi-Agent Interval Compressed Therapy for Patients With High-Risk Rhabdomyosarcoma (**ARST08P1**) | COG Contact 717-531-6012 |
| McGregor, Lisa | PSHCI-12-031 | A Randomized Phase II Trial of Bevacizumab (IND# 7921, Avastin) and Temsirolimus (IND# 61010, Torisel) in Combination with Intravenous Vinorelbine and Cyclophosphamide in Patients with Recurrent/Refractory Rhabdomyosarcoma (**ARST0921**) | COG Contact 717-531-6012 |
| McGregor, Lisa | PSHCI-11-060 | A Phase I/II Clinical Study of Vorinostat in Combination with Etoposide in Pediatric Patients < 21 Years at Diagnosis with Refractory Solid Tumors | Kathryn Byrnes 717-531-3098 |
| **SYMPTOM MANAGEMENT/SUPPORTIVE CARE** | | | |
| McGregor, Lisa | COG-ALTE05N1 | Umbrella Long-term Follow-up Protocol | COG Contact 717-531-6012 |
| McGregor, Lisa | COG-ALTE07C1 | Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children with Cancer | COG Contact 717-531-6012 |
| Freiberg, Andrew | PSHCI-12-065 | An open-label, cross-over, pharmacokinetic study to assess the safety and pharmacokinetics of transdermal granisetron (Sancuso® patch) and IV granisetron in a pediatric oncology population (ages 13-17) | Julie Vallati 717 531 3049 |